JP2022525318A5 - - Google Patents

Info

Publication number
JP2022525318A5
JP2022525318A5 JP2021555228A JP2021555228A JP2022525318A5 JP 2022525318 A5 JP2022525318 A5 JP 2022525318A5 JP 2021555228 A JP2021555228 A JP 2021555228A JP 2021555228 A JP2021555228 A JP 2021555228A JP 2022525318 A5 JP2022525318 A5 JP 2022525318A5
Authority
JP
Japan
Prior art keywords
cell
chimeric antigen
amino acid
antigen receptor
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021555228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525318A (ja
JP7602803B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/020436 external-priority patent/WO2020190483A1/en
Publication of JP2022525318A publication Critical patent/JP2022525318A/ja
Publication of JP2022525318A5 publication Critical patent/JP2022525318A5/ja
Priority to JP2024194375A priority Critical patent/JP2025013530A/ja
Application granted granted Critical
Publication of JP7602803B2 publication Critical patent/JP7602803B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021555228A 2019-03-15 2020-02-28 Ｃｄ１４７キメラ抗原受容体および使用の方法 Active JP7602803B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024194375A JP2025013530A (ja) 2019-03-15 2024-11-06 Ｃｄ１４７キメラ抗原受容体および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819403P 2019-03-15 2019-03-15
US62/819,403 2019-03-15
PCT/US2020/020436 WO2020190483A1 (en) 2019-03-15 2020-02-28 Cd147 chimeric antigen receptors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024194375A Division JP2025013530A (ja) 2019-03-15 2024-11-06 Ｃｄ１４７キメラ抗原受容体および使用の方法

Publications (3)

Publication Number Publication Date
JP2022525318A JP2022525318A (ja) 2022-05-12
JP2022525318A5 true JP2022525318A5 (enExample) 2023-02-24
JP7602803B2 JP7602803B2 (ja) 2024-12-19

Family

ID=72520374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021555228A Active JP7602803B2 (ja) 2019-03-15 2020-02-28 Ｃｄ１４７キメラ抗原受容体および使用の方法
JP2024194375A Withdrawn JP2025013530A (ja) 2019-03-15 2024-11-06 Ｃｄ１４７キメラ抗原受容体および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024194375A Withdrawn JP2025013530A (ja) 2019-03-15 2024-11-06 Ｃｄ１４７キメラ抗原受容体および使用の方法

Country Status (6)

Country Link
US (1) US20220152106A1 (enExample)
EP (1) EP3938402A4 (enExample)
JP (2) JP7602803B2 (enExample)
CN (1) CN113853390B (enExample)
CA (1) CA3132458A1 (enExample)
WO (1) WO2020190483A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201652A1 (en) * 2020-12-11 2022-06-16 Xiaoping Bao Human chimeric antigen receptor neutrophils, compositions, kits and methods of use
EP4268991A4 (en) * 2020-12-22 2024-10-30 Araki Technical And Research Co., Ltd. DEVICE FOR PRODUCING A BRANCHING PARTIAL STRUCTURE IN A METAL PIPE AND METHOD FOR PRODUCING A BRANCHING PARTIAL STRUCTURE IN A METAL PIPE
AU2023213691A1 (en) * 2022-01-28 2024-09-05 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
WO2024220483A2 (en) * 2023-04-19 2024-10-24 Rutgers, The State University Of New Jersey Grp78 chimeric antigen receptors and combination therapies for treating cancer
WO2025105442A1 (ja) * 2023-11-15 2025-05-22 大塚製薬株式会社 キメラ抗原受容体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7333794A (en) * 1993-08-02 1995-02-28 Houston Biotechnology Incorporated Single-chain immunotoxin compositions and methods for preventing secondary cataracts
CN102316898A (zh) * 2008-09-29 2012-01-11 森托科尔奥索生物科技公司 抗cd147抗体、方法和用途
BR112017013981A2 (pt) * 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
CN107709356A (zh) * 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
WO2018165619A1 (en) * 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof

Similar Documents

Publication Publication Date Title
JP2022525318A5 (enExample)
JP2022191241A5 (enExample)
JP2020503015A (ja) 抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞
JP7269167B2 (ja) モジュラー四価二重特異性抗体プラットフォーム
JP2024023228A5 (enExample)
JP2025020138A (ja) 免疫細胞活性化のための二重特異性抗体
JP2019513370A5 (enExample)
CN109651511B (zh) 一种靶向bcma的嵌合抗原受体及其应用
CA3093008C (en) Monoclonal antibodies that bind to the embryonic stage-specific antigen 4 and their uses
JP2019537433A5 (enExample)
JP2015513920A5 (enExample)
JP2023507729A5 (enExample)
US11945878B2 (en) Switch molecule and switchable chimeric antigen receptor
CN109796532B (zh) 靶向成纤维激活蛋白α的结合单元及其应用
IL264144B1 (en) Antibody 18a2 against claudin and its use
Qian et al. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing
WO2012020622A1 (ja) ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
JP2022527081A5 (enExample)
JP2020522473A5 (enExample)
JP2020501512A5 (enExample)
JP2021501587A5 (enExample)
JP2021534784A5 (enExample)
US20240400705A1 (en) Composition of recombinant antigen binding molecules and method of making and using thereof
JP2022521240A5 (enExample)
JP2024515919A5 (enExample)